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During the last decade RNA-based therapy had a burst of interest due to all 
undeniable advantages such as high selectivity, low off-target toxicity, and the 
potential scalability to a large repertory of untreatable human diseases. Most RNA 
therapeutic molecules are inhibitory RNAs and have been developed to down-regulate 
expression of pathogenic genes. Nevertheless, a large group of diseases would strongly 
benefit from the discovery of RNAs able to increase gene expression and restore 
physiological transcription and/or translation of a specific target when low expression 
is pathogenic. 
Recently, gene-specific transcriptional activating RNAs (RNAa) (1) and non-
degradative antisense oligonucleotide (ASOs) (2) have been largely employed to 
increase the expression of selected genes. On the other hand, despite its great potential, 
long non-coding translational activation as therapeutic tool is still at its infancy. 
We have previously described SINEUPs, natural and synthetic antisense long 
non-coding RNAs, which promote translation of partially overlapping mRNAs 
through the activity of an embedded SINEB2 domain. In this study, we focused the 
attention on the SINEUP-mediated up-regulation as a possible treatment to rescue 
haploinsufficient gene-dosage. 
In this context, we developed SINEUPs for Friedreich’s ataxia (FRDA), a life-
threatening disease with neuro- and cardio-degenerative progression (3) representing 
the most frequent type of inherited ataxia, and affecting more than 15,000 patients in 
Western countries (4). This monogenic disease is caused by the hyperexpansion of 
naturally occurring GAA repeats in the first intron of the frataxin (FXN) gene, 
encoding for frataxin, a protein implicated in the biogenesis of iron-sulphur clusters. 
As the genetic defect interferes with FXN transcription, FRDA patients express a 
normal frataxin protein but at insufficient levels. Thus, current therapeutic strategies 
are mostly aimed to restore physiological FXN expression. 
The first goal of our study was to synthesize and validate in different cell systems, 
the strongest and shortest functional FXN-specific SINEUP to increase endogenous 
frataxin protein levels with a post-transcriptional mechanism. 
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Secondly, we aimed to validate SINEUPs as RNA tools of protein synthesis in 
FRDA-derived cell lines and, finally, to investigate its capability to functional rescue 
FRDA cells defects in cellular aconitase activity, one of the hallmarks of the disease. 
In summary, we identify by in vitro screening FXN-specific SINEUPs promoting 
the recovery of disease-associated defects in patient-derived cells. Thus, we provide 
evidences that SINEUPs may be the first gene-specific therapeutic approach to activate 
FXN translation in FRDA and, more broadly, a novel scalable platform to develop new 




AAV, adeno-associated virus; 
ACO, Aconitase enzyme; 
ACT, Actin beta; 
AGO2, argonaute 2; 
AS Uchl1, lncRNA antisense to UchL1 mRNA; 
AS, antisense; 
ASOs, antisense oligonucleotides; 
ATP, adenosine triphosphate; 
BD, binding domain; 
bp, base pair; 
cDNA, complementary DNA; 
CDS, coding sequence; 
ciRNA, circular RNA 
cox7B, cytochrome c oxidase subunit 7B; 
CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats; 
CTCF, CCCTC-binding factor; 
DGCR8, DiGeorge syndrome critical region gene 8; 
DICER, endoribonuclease Dicer or helicase with RNase motif; 
ds, double-stranded 
ED, effector domain; 
ENCODE, Encyclopedia of DNA Elements; 
EPO, erythropoietin; 
eRNA, enhancer RNA; 
FANTOM, Functional Annotation of the Mammalian Genome; 
FAST-1, frataxin antisense transcript 1; 
FBS, fetal bovine serum; 
FRDA, Friedreich Ataxia; 
FXN, frataxin gene; 
GAPDH, Glyceraldehyde-3-phosphate dehydrogenase 
GFP, green fluorescent protein; 
GUSB, glucuronidase beta 
HDAC, Histon deacetylase; 
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HEK, human embryonic kidney; 
HRP, horseradish peroxidase; 
IC50, inhibitor concentration that decreases the biotransformation of a substrate at a 
single, specified concentration by 50%; 
iFXN, intermediate frataxin protein; 
invSINEB2, inverted SINE of B2 subfamily; 
invSINEB2, inverted SINEB2; 
ISC, Iron-Sulphur Cluster; 
lincRNA, long intergenic non-coding RNA; 
LINE, long interspersed elements; 
lncRNA, long non-coding RNA; 
LOFA, late-onset FRDA; 
mFXN, mature frataxin protein; 
MIRb, mammalian interspersed repetitive (MIR) element b; 
miRNA, micro RNA; 
MOE, methoxyethyl; 
MOI, multiplicity of infection; 
MPP, mitochondrial processing peptidase; 
MRC, mitochondrial respiratory chain; 
mRNA, messenger RNA; 
ncRNA, non-coding RNA; 
NMHV, nuclear localization signal – MS2 coat protein interacting domain – HA 
epitope – (3x) VP16 transactivating domain; 
nt, nucleotide; 
ORF, open reading frame; 
PD, Parkinson's disease; 
piRNA, piwi-interacting RNA; 
PRC2, polycomb repressor complex 2; 
pri-miRNA, primary miRNA; 
qRT-PCR, quantitative real time PCR; 
RIKEN CLST, Center for life science technologies; 
RIKEN PMI, Preventive Medicine & Diagnosis Innovation Program; 
RISC, RNA-induced silencing complex; 
RNA Pol, RNA polimerase; 
RNAa, activating RNA; 
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RNAi, RNA interference; 
RNase H, Ribonuclease H; 
rRNA, ribosomal RNA; 
RT, retrotranscriptase; 
S, sense; 
saRNA, small activating RNA; 
SH-SY5Y, human neuroblastoma bone marrow; 
shRNA, short harping RNA; 
SINE, short interspersed element; 
SINEB2, short interspersed element of B2 subfamily; 
SINEUP, AS lncRNA with embedded inverted SINE B2 element that UP-regulate 
target mRNA translation; 
siRNA, short-interfering RNA; 
snoRNA, small nucleolar RNA; 
SOD1, superoxide dismutase 1; 
SSOs, spice-switching oligonucleotides; 
TRBP, TAR RNA-binding protein; 
tRNA, transfer RNA; 
TSS, Transcriptional Start Site; 
UchL1, Ubiquitin carboxyl-terminal hydrolase L1; 
UTR, untranslated region; 
VEGF, vascular endothelial growth factor; 
VLOFA, very late-onset FRDA; 





RNA THERAPEUTICS: THE PRESENT STATE 
The discovery of catalytic RNAs and RNA interference (RNAi) in the 1980s and 
the 1990s are milestones in the understanding of RNA function. No longer an 
intermediate between DNA and protein, but a dynamic and adaptable molecule able to 
regulate gene function (5) (6) (7). It’s the breakthrough that will revolutionise 
molecular medicine, enlarging the range of “drug-able” targets and the ability to 
manipulate potentially every target transcript. 
In this context, these new therapeutic drugs should be broadly classified as 
inhibitory RNAs or activatory RNAs. The former, promote gene expression down-
regulation and include small antisense oligonucleotides (ASOs) (8,9), small interfering 
RNAs (siRNAs), and short hairpin RNAs (shRNAs,) (10) (11) . The latter, equally 
challenging, include RNAs able to activate gene-specific transcription (activatory 
RNA, RNAa) as well as enhance target translation (SINEUP, described in the next 
chapter) (12). 
RNA molecules are unstable, potentially immunogenic and requires a vehicle to 
be driven to targeted cells. Nevertheless, dozens of RNA-based therapeutics are 
currently under clinical investigation, more than 50 RNA or RNA-derived therapeutics 




AntiSense Oligonucleotides (ASOs) 
Short, single-stranded antisense oligonucleotides (ASOs) are sequence-specific 
RNAs, tipically 8-50 nucleotides long, that bind target RNA molecules by Watson-
Crick base pairing (13) and inhibit gene expression by altering mRNA splicing, 
arresting mRNA translation by blocking its recognition by the ribosomes, and inducing 
target degradation by RNase H (14) (15). 
 
Figure 1 - Antisense mechanisms. ASOs can interact with RNA transcripts including both pre-mRNA and 
mature mRNA in the nucleus and in the cytoplasm respectively. Exonic, intronic, and untranslated region (UTR) 
sites may be targeted. The chemistry and design of ASOs impact on post-binding events that can be initiated 
including modulation of mRNA maturation, RNase H-mediated degradation, and steric translation inhibition 
(16). 
Like others RNA-derived drugs, ASOs usually include chemical modifications 
to enhance its properties. Primary nucleotide sequence may be modified such as 
phosphorothioate (PS or PS ASOs) backbone modification; 2’-O-methyl (2’-O-Me), 
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2’-fluoro (2’-F) and 2’-O-methoxyethyl (2’-MOE) sugar substitution, and 2’-O-4’-C-
methylene linked bicyclic ribonucleotides (locked nucleic acid, LNA) (17) (14) (18) 
(19). 
 
Figure 2. Common ASO modification. a) Phosphate backbone modifications: native, anionic charged 
phosphodiester; charged phosphorothioate; neutral phosphotriester; neutral morpholino backbone (PMO) and 
peptide nucleic acid (PNA) backbones align nucleobases with native mRNA nucleobase spacing. b) Common 
2′ modifications of the sugar: native 2′-hydroxyl (OH), 2′-fluoro (F), 2′-hydroxymethyl (20), 2′-methoxyethyl 
(MOE) and 2′,4′-bicyclics that contain O-methylene bridge or locked nucleic acid (LNA) (21). 
Modifications at the 2’-position both enhance mRNA target binding on one hand 
and interfere negatively with RNaseH thus preventing target RNA cleavage. 
“Gapmers” design have been adopted to leave the central region (gap) unmodified in 
between the flanking 2’-modified regions. This configuration allows RNaseH 




Figure 3. Antisense oligonucleotide (ASO) ‘gapmer’ design. The phosphorothioate backbone provide 
nuclease resistance, while the 2’-sugar modification exclusively on first and last nucleotides increases target 
RNA binding affinity on the outer portions of the ASO. Unmodified nucleotides allows RNaseH cleavage at the 
central region of the ASO (22) 
To date, this class is the most widely used for therapeutical applications. In this 
contest, MOE ASOs gapmers targeting mutant SOD1 are the first example of ASOs 
tested in human clinical trials to treat ASL (Amyotrophic Lateral Sclerosis) (22). 
RNA interference (RNAi) 
RNA interference is the cellular process of gene expression silencing mediated 
by small RNA acting at both post-transcriptional and transcriptional levels, throught 
transcriptional gene silencing is not currently use for clinical purposes (23). 
microRNAs (miRNA), siRNAs and Piwi-Interacting RNAs (piRNAs) comprise small 
RNAs involved in RNAi. Among them, piRNAs are still poorly characterized in 
mammals (24) (25). 
Post-transcriptional gene silencing is exploited by target mRNA degradation or 
cleavage. The first, is mediated by endogenous miRNA that, through imperfect 
complementarity, induce target degradation. On the other hand, sequence-specific 
cleavage is accomplished by both exogenous siRNAs or shRNAs having perfect or 
near-perfect base pairing with the target. After the cleavage, the target mRNA follows 
the natural degradation pathway, and therefore both endogenous and exogenous small 
RNAs-mediated processing share almost the same endogenous factor. Thus, 
siRNA/shRNA therapeutics may compete with natural miRNAs.  
Broadly, primary miRNAs (pri-miRNAs) are processed by Drosha and DGCR8 
(DiGeorge syndrome critical region gene 8) complex and then incorporated into pre-
RISC (pre RNA induced silencing complex) complex formed by Dicer and TAR RNA-
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binding protein (TRBP) (26). Likewise, Dicer/TRBP complex process both shRNAs 
and dsRNA (double-stranded RNAs) molecules into ≈21-23-nt long siRNAs. One 
strand of the siRNA, guide or passenger, may direct sequence-specific cleavage of 
target mRNA through RISC. AGO2, Argonaute 2, component of RISC has 
endonuclease activity by which target mRNA is cleaved and subsequently degraded 
by exonucleases (27). Inside RISC, the guide siRNA strand can be use to target other 
complementary mRNAs. 
All the abovementioned properties have inspired the usage of synthetic siRNA 
molecules for therapeutical knockdown of endogenous and viral mRNAs (28). 
 
 
Figure 4 - RNAi and miRNA Biogenesis. Pri-miRNAs are transcribed from either endogenous or vector-
derived genes by RNA polymerase II or polymerase III. The pri-miRNA transcript enters the microprocessor 
complex (Drosha & DGCR8) for its first cleavage event. The resulting pre-miRNA, as well as vector-derived 
shRNAs, can then be bound by the Exportin 5 RanGTP shuttle and exported though a nuclear pore into the 
cytoplasm. In the cytoplasm, pre-miRNAs and shRNAs associate with Dicer and TRBP. Following cleavage 
event results in the production of 22-nt-long miRNA/miRNA* duplex. The guide strand of the duplex is then 
preferentially loaded into Ago, whereas the passenger strand is usually degraded (29). 
RNAi in mammals commonly deliver synthetic siRNA molecules ≈19-23 base 
pairs, with overhangs at both 3’, in order to mimic Dicer cleavage product. However 
symmetrical overhangs interfere with RISC strand choice since either guide or 
passenger strands can be selected. To avoid the selection bias, the dsRNA may be 
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designed asymmetrically with one end blunt and the second overhanging, directing 
preferentially the guide strand biogenesis, and thereby increasing siRNA potency and 
decreasing off-target effect (30). 
shRNAs may constitutively be expressed from promoters and therefore induce 
long-lasting gene silencing for the duration of their transcription and biogenesis. 
However, since they are expressed through strong RNA Pol III promoters, the natural 
miRNA machinery could saturate resulting in severe toxicity (31) (32). To overcome 
saturation, multiple shRNAs may be expressed as multicistronic transcript from RNA 
Pol II or combined with non-RNAi therapies like rybozymes and RNA decoys (33) 
(34). 
Recently, significant progress has been made in terms of siRNA/miRNA 
delivery. The most commonly used are viral vectors, both lentiviral and adeno-
associated for brain delivery (35). 
Anti-miRNA oligonucleotides (AntagoMIR) 
Dysregulation of endogenous miRNA has been liked to numerous disorders (36) 
such as cancer, autoimmune disease, and neurodegeneration. Therefore, therapeutic 
strategies to regulate miRNA activity are emerging. To date, the expression of miRNA 
sponges, small RNA competitive inhibitors, and anti miRNA ASOs (antagoMIR, anti-
miRNA or blockmir) (37) (38) are the main strategies could be adopted to achieve 
down-regulation of miRNA activity. Above all, small RNA competitive inhibitors are 
not currently used as therapeutical approach due to poor specificity and high IC50 (). 
Long non-coding RNA (lncRNAs), such as lincRNAs and pseudogenes, may 
selectively bind miRNA and thus competing with their targets and reducing the 
quantity of active miRNA (39) (40). Hence synthetic sponge may be assembled as 
composed by long non-coding transcripts containing multiple copies of the binding 
site of the target miRNA. However, their usage is still restricted to in vitro application 
and some pre-clinical testing (38). Recently, a new class of nuclear-resistant lncRNAs, 
known as circular RNAs (circRNAs), has been discovered. Generated by covalent link 
of 5’ and 3’ termini (41) (42), may act as miRNAs sponge competing with both 
lncRNAs and protein-coding RNAs. 
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miRNA inhibition through antagoMIR, single-stranded ASOs, is currently the 
technique of choice. AntagoMIR targeting different miRNAs has been developed for 
Hepatitis C virus infection, liver cancer, heart failure, and heart metabolic disorders 
(2). Among them, Miravisien (SPC3649), specifically inhibiting human endogenous 
liver-specfic miRNA required for Hepatitis C virus infection (miR-122) had 
successfully completed two Phase I trials. Already indicated as well tolerated and safe, 
Miravisien has recently advanced to Phase II clinical study (43). 
Activatory RNAs 
Non-degradative ASOs 
Taking advantage of its property to bind miRNAs, ASOs has also been employed 
for up-regulating gene expression by different mechanisms such as i.e. interfering with 
miRNA-mediated mRNA degradation pathway (2). Moreover, if designed against 
antisense (AS) lncRNAs involved in chromatin remodelling, they can block Polycomb 
Repressor Complex 2 (PRC2) assembly allowing transcription to restart (44). 
Otherwise, exon-skipping ASOs or splice-switching oligonucleotides (SSOs), can 
modulate mRNA processing by targeting pre-mRNA and thus interfering with 
splicing. (9). This last strategy has been used in the clinic for a variety of diseases, like 
Duchenne Muscolar Dystrophy (45) (46) (47), Ataxia Telangectasia (48,49), 
Frontotemporal Dementia and Parkinsonism linked to chromosome 17 (50). 
RNA activation (RNAa) 
Small RNAs able to enhance transcription, RNAa, were first described in 2006 
by Li and colleagues (51). siRNA-like molecules have been found to elicit a specific 
and prolonged stimulation of Cadherin E, p21 and VEGF transcription by targeting 
their promoters. Later on, several reports have corroborated natural RNAa as a 
pervasive phenomenon (52) (53) (54) (55) (56). 
Commonly referred as small activating RNAs (saRNAs), they may be sense or 
antisense oriented (56) and usually directed against transcription start sites (57) (58) 
(59) or surrounding polyA-site sequences (60), conserved cis-active elements of the 
gene of interest (56), and the transcribed region of the gene (61). 
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Although RNAa dynamics are still poorly understood, two classes of molecular 
mechanism can be identified. saRNAs may act binding AS transcript and theredore 
preventing down-regulation of its sense cognate (62) (63) (1) or saRNAs may convey 
transactivating macromolecular complexes to gene locus (62) (59) (64). Even if 
mismatches are quietly tolerated, they should not involve saRNA 5’ end (58). 
Two key features make them extremely promising, they display a later onset 
compared to RNAi and may exert a prolonged effect over 7 days (58). They elicit 
mRNA up-regulation that is usually within physiological ranges (56) (52) (65). 
NMHV transcription factors 
Recently, a new class of artificial transactivators has been developed. These are 
RNA-programmable enzymes, named NMHV (Nuclear localization signal - MS2 coat 
protein RNA interacting domain - HA epitope - (3x) VP16 transactivating domain) 
(66). This small and non-CRISPR-based device mainly consists of a fully synthetic, 
ribonucleoproteic transcription factor that stimulates transcription and a non-coding 
RNA "bait" domain that specifically drives the whole ribonucleoprotein to the target 
gene of interest (66). The two elements are kept together by two ancillary domains. A 
polypeptidic MS2 RNA-interacting domain (67), covalently joined to the 
ribonucleoproteic transcription factor and forming the polypeptidic "apo-factor", and 
its corresponding hairpin RNA interactor (68) (69), covalently joined to the non-
coding RNA "bait" domain forming the RNA "co- factor". 
This transactivator is 7-fold smaller than the CRISPR counterpart and, moreover, 
is active only where genes are normally expressed. Hence, it avoids potentially 
detrimental ectopic gene activation. Potentially capable of ad libitum gene stimulation, 
NMHV elicit a transcriptional gain around 2-folds. Although extremely promising to 
rescue insufficiency, NMHV requires further experimental validation. 
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SINEUPS: A NEW FUNCTIONAL CLASS OF ANTISENSE LNCRNAS 
Large-scale genomic projects, such as FANTOM (70); FANTOM Consortium 
and the RIKEN PMI and CLST (DGT) and ENCODE (71) (72) marked the beginning 
of the so called “post-genomic era”, by developing of full genome sequencing 
techniques. In this context, it was discovered that the vast majority (70-80%) of the 
mammalian genome is transcribed. Protein-coding gene represent just a small fraction 
(1-2%) of the transcriptionally active regions, therefore this prevalent transcription 
produces an extensive repository of non-coding (ncRNAs), including small ncRNAs, 
long non-coding RNAs (lncRNAs) and RNAs of Transposable Elements (TEs), 
increasing complexity in gene regulatory networks. 
Among them, lncRNAs represent the widest and most heterogeneous class of 
transcripts exceeding 200 nucleotides in length. According to LNCipedia v3.1, the 
human genome counts more then 90000 lncRNAs transcripts differing in size, 
anatomical properties, subcellular localization and biological functions (73) (74). 
However, they share features which include: being transcribed by RNA polymerase II, 
to undergo splicing, to present 5′ caps and being polyadenylated (75). Moreover, their 
organization into discrete domains seems to represent an additional common 
denominator, by which lncRNAs can recruit and coordinate the activity of multiple 
effectors. Despite, their primary sequences are poorly conserved, whilst showing 
several similarities in lncRNAs modes of action, thus reinforcing the importance of 
RNA structures in determining function.  
Based on genomic location relative to their neighbouring protein-coding genes, 
lncRNAs can be classified as intergenic (long intergenic non-coding RNAs or 
lincRNAs) if they do not overlap with any other gene or, alternatively, may overlap to 
genes in exonic, intronic or fully overlapping configuration. 
lncRNAs contribute to gene expression regulation and, moreover, have been 
reported to be involved in normal organism development as well as in disease (76) 
(77) (78). While nuclear lncRNAs can regulate transcription in cis or trans (79), 
cytoplasmic ones contribute to post-transcriptional gene expression regulation by 
“sponging” miRNAs, sequestering specific proteins, modulating translation, and 
finally interacting with ribosomes (80) (81) (82) (39) (83) (84). Interestingly, examples 
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of lncRNAs shuttling across different cellular districts in response to specific stimuli 
have also been reported (82) (85). lncRNAs function are summarized in Figure 5. 
 
 
Figure 5 - Classification of lncRNA functions. (A) LncRNAs can recruit different protein components of the 
chromatin remodelling complex to change the chromatin organizational patterns. (B) They can act as ‘sponges’ 
by base pairing with their complementary miRNAs and reducing their effects. (C) LncRNAs can play 
scaffolding roles by providing docking sites for proteins that function together in the same biological pathway. 
(D) They activate transcription of certain genes by guiding transcription factors to their promoters. (E) LncRNAs 
are capable of suppressing transcription by sequestering transcription factors and keeping them away from their 
promoters. They can modulate mRNA functioning through base pairing with them and (F) inhibiting their 
translation (G) altering their splicing patterns and (H) subjecting them to degradative pathways (86). 
One of the main features of genomes is that different genes residing in opposite 
DNA strands can co-exist within the same genomic region. As a result of bidirectional 
transcription, overlapping natural sense/antisense (S/AS) pairs are generated (72) (87) 
(88). Approximately 61-72% of all transcribed regions in mouse and human present 
lncRNAs that are in antisense orientation to adjacent protein-coding genes (87) (89). 
S/AS pairs are classified according to their reciprocal genomic organization as 5' 





Figure 6 - Classification of sense/antisense (S/AS) pairs. Sense genes are in green, AS genes in blue. Arrows 
indicate 5 to 3 direction. Gray box indicates regions of overlap. Adapted from (90) 
AS lncRNAs have been demonstrated to modulate cognate protein-coding gene 
expression in different modes (91), by affecting the epigenetic state of chromatin (92), 




Among the mouse genomic loci of Parkinson’s disease-associated genes, Carrieri 
and colleagues identified a spliced lncRNA transcript in the murine Ubiquitin carboxy 
terminal hydrolase 1 (Uchl1)/PARK5 gene, mapping in antisense orientation to its 
protein-coding counterpart (82). 
Named Antisense Uchl1 (AS Uchl1), this 5' head-to-head divergent lncRNA, 
initiates within the second intron of Uchl1 and overlaps the first 73 nts of the sense (S) 
mRNA including the AUG codon (-40/+33 from ATG). The non-overlapping part of 
the transcript contains two embedded repetitive sequences, SINEB1 of the F1 subclass 
(Alu) and SINEB2 of the B3 subclass (82) (Figure 7). 
 
 
Figure 7 - Uchl1/AS Uchl1 genomic organization. Uchl1 exons are in black: 3’ and 5’ UTRs are in white; AS 
Uchl1 exons are in grey; repetitive elements are in red (Alu) and in blue (SINEB2); introns are indicated as 
lines. Adapted from (82). 
In mouse, AS Uchl1 is co-expressed in 40% of tissues that present Uchl1 mRNA, 
but no AS Uchl1 is found in the absence of sense transcript (82). The two transcripts 
are differently localized. While mature Uchl1 mRNA is predominantly detected in the 
cytoplasm, AS Uchl1 is in the nucleus (82). 
Overexpression of AS Uchl1 is accompanied by an increase of UCHL1 
endogenous protein. Interestingly, produces no changes in Uchl1 mRNA levels, thus 
suggesting that AS Uchl1 expression regulation occurs at post-transcriptional level 
(82). Selective deletion of AS Uchl1 sequence elements to have led to the 
identification of two functional domains responsible for AS Uchl1-mediated 
translation upregulation: the 5' overlapping region and the inverted SINEB2 element. 
AS Uchl1 physiologically accumulates in the nucleus of dopaminergic neurons. 
However, it shuttles into the cytoplasm upon cellular stress - as induced by rapamycin, 
an inhibitor of CAP-dependent translation – where promotes translation of sense 
protein-coding mRNA by enhancing its association to heavy polysomes (82).  
 13 
Natural SINEUPs 
A large group of lncRNAs shares similar features to S/AS Uchl1, in which 
FANTOM3 identified 31 natural S/AS pairs. Recently, functional validation proved 
their analogous function (90), as is the case of AS Uxt reported to enhance endogenous 
Uxt protein synthesis when overexpressed in MN9D cells with unaffected Uxt mRNA 
levels (82). AS Uchl1 can therefore be considered as the representative member of a 
new functional class of natural antisense lncRNAs capable of up-regulating translation 
of sense overlapping transcripts. The combination of two RNA elements provides its 
biological activity: the overlapping region (Binding Domain, BD) confers target 
specificity, while the embedded inverted SINEB2 element (Effector Domain, ED) is 
required for translation enhancement (Figure 8). These lncRNAs are referred to as 
SINEUPs, as they rely on a SINEB2 sequence to UP-regulate translation in a gene-
specific manner (90,95). 
 
Figure 8 - Schematic representation of SINEUPs. SINEUP modular structure. SINEUP binding domain 
(grey): SINEUP sequence that overlaps, in antisense orientation, to the sense protein-coding mRNA. SINEUP 
effector domain (blue): non-overlapping portion of SINEUPs (grey), containing the inverted SINEB2 element 
(invB2) that confers activation of protein synthesis. 5′ to 3′ orientation of sense and antisense RNA molecules 
is indicated. Structural elements of protein-coding mRNA are shown: 5′ untranslated region (5′UTR, white), 
coding sequence (CDS, black) and 3′ untranslated region (3′UTR, white). 
The modular organization of SINEUPs strongly reflects the role of embedded 
TEs in shaping lncRNAs functional features (82) (95). In particular, TEs could provide 
binding sites for specific molecular complexes regulating SINEUP activity. At the 
same time, antisense, overlapping regions may confer target specificity through 
RNA/RNA and RNA/DNA pairing. 
However, the exact mechanism underlying the activity of the inverted SINEB2 
as ED of SINEUPs remains elusive. 
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invSINEB2: structure and function 
Recently, Podbevšek and colleagues described the secondary structure of the 
invSINEB2 element of AS Uchl1 (183 nts long) taking advantage of chemical 
footprinting and NMR studies. It folds into a structure with mostly helical secondary 
structure elements and it exhibits several bulges, asymmetric internal loops and 
hairpins (Figure 9).  
 
Figure 9 - Secondary structure of the inverted SINEB2/183 effector domain of AS Uchl1. tDMS and CMCT 
reactive nucleotides are shaded in blue and red, respectively. Internal loops and stem-loops are labelle as ILx 
and SLx, respectively. Non-reactive nucleotides are only circled. The segment shaded in gray corresponds to 
the DNA primer hybridization site (96). 
Moreover, within invSINEB2, the terminal SL1 represent a crucial structural 
determinant required for AS Uchl1 activity. The deletion of nucleotides 68–77 of 
invSINEB2 (ΔSL1) from the full length AS Uchl1 (ΔSL1 mutant) completely abolish 
the ability of AS Uchl1 RNA to up-regulate UchL1 protein levels (Figure 10) 
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Figure 10 - The SL1 hairpin contributes to AS Uchl1 activity. (A) Murine neuroblastoma N2a cells were 
transfected with AS Uchl1 and ΔSL1 mutant constructs. Control cells were transfected with an empty control 
plasmid. Protein (97) and RNA (bottom) levels showed killed activity of ΔSL1 mutant RNA. (B) Graphical 
representation of AS Uchl1 and ΔSL1 translation enhancement activity on endogenous Uchl1 mRNA in N2a 
cells (N=5). *, p=0.01; NS, not significant (p>0.5) (96). 
Further studies are needed to elucidate the precise mechanism to increase protein 
translation by the embedded invSINEB2 and to determine whether the SL1 motif is 




Carrieri and colleagues engineered a chimeric construct, named AS GFP, by 
swapping AS Uchl1 BD to Uchl1 with a complementary sequence to EGFP mRNA in 
antisense orientation, maintaining the whole 3' tail (about 1200 nucleotides), the 
inverted SINEUB2 and the partial Alu repeat (Figure 11). This first synthetic SINEUP 
succeeded in up-regulating GFP protein translation when co-transfected with 
corresponding sense GFP-encoding DNA in HEK 293T cells, with no effects on GFP 
mRNA levels (Figure 11) (82) (95). 
 
Figure 11 - Synthetic AS lncRNA increases target protein levels. (A)Scheme of antisense GFP construct. Δ 
5’ AS Uchl1 with repetitive elements (SINEB2, red; Alu, blue) and the overlap (green) regions are indicated. 




Moreover, Yao and co-workers showed that GFP mRNA is recruited to heavy 
polysomes in AS GFP (there referred to as RNAe)-transfected cells (98) as previously 
shown for Uchl1 mRNA recruitment triggered by natural AS Uchl1 (82). 
Collectively, taking advantage of SINEUPs domain architecture, artificial 
SINEUPs may be designed by manipulating the BD to enhance target mRNA 
translation of any target of interest. Therefore, the translational regulatory properties 
of natural SINEUPs are retained by synthetic ones, likely shearing common molecular 
mechanisms, suggesting their applications as tools to selectively modulate gene 





Evidence of SINEUPs scalability paves the way towards a potential application 
as therapeutic approach, particularly in haploinsufficient diseases. However, its 
applicability is limited by RNA length. About 1200 nts long transcripts are suitable for 
delivery systems such as viral vectors, but incompatible with the use as naked RNA 
therapeutic molecules. 
The laboratory of Prof. Gustincich demonstrated that deletions in redundant 
portions of the non-overlapping regions of AS Uchl1 don’t affect its functionality. The 
exclusive combination of the invSINEB2 sequence with AS GFP BD, called 
miniSINEUP-GFP, promotes GFP protein up-regulation at post-transcriptional level 
(Figure 12). Then, they showed that ≈250 nt long transcripts are able to retain both 
activity and mechanisms of their full-length counterparts for  a wide spectrum of 
targets and in different cell types (95) (99) (100). 
 
 
Figure 12 – miniSINEUP-GFP Activity. (A) Domain organization of miniSINEUP-GFP. Binding (gray) and 
effector (invB2, red) domains are indicated. (B) HEK 293T/17 cells were co-transfected with sense GFP vector 
together with empty vector (-SINEUP), SINEUP-GFP as positive control (+SINEUP) and miniSINEUP-GFP 
(+miniSINEUP). From (95).  
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SINEUPs as a new platform for increasing gene expression  
The discovery of a new functional class of natural and synthetic antisense 
lncRNAs that stimulate translation of sense mRNAs paves the way to interesting 
biotechnological and therapeutical applications. The modular architecture of SINEUPs 
enables engineering synthetic molecules against potentially any target of interest, by 
swapping the BD.  
Three major applications can be envisioned. 
1. Molecular biology. SINEUPs can be used as a toolkit for increasing 
expression of the gene of interest in molecular biology experiments. 
Scientists may consider them as a counterpart of siRNA technologies. 
2. Biotechnology. They can be used to increase efficiency of protein 
manufacturing procedures. Data are shown by different laboratories that 
SINEUPs can increase i.e. production of recombinant antibodies. 
3. Therapy. SINEUP technology presents two critical properties for their use in 
therapy: high specificity and low side effects. The former is ensured by fine-
tuned BD design. The latter derives from the capability to gently elicit 
translational gains within physiological range. Moreover, target gene 
stimulation occurs only where the gene is normally expressed, avoiding 
detrimental ectopic translational activation. In this context, there are several 
examples when genes causing haploinsufficient diseases may lead to other 
diseases when duplicated or their protein products are over-expressed in large 
quantities. A miniaturized version, known as miniSINEUP, implements the 
power of the tool, overhauling length as the main obstacle of SINEUP 
application in RNA therapeutics: However, delivery systems and chemical 
modifications to ensure SINEUP activity preservation are still under 
investigation. These features determine the applicability of SINEUPs as a 
new platform for increasing gene expression in vivo for therapy. Currently, 
several therapeutic needs for haploinsufficiency treatments are still unmet. 
Since the reduction to 50% or less of gene expression results in an abnormal, 
pathological phenotype, an efficient and specific SINEUP activity would be 
in principle curative by restoring physiological target levels of gene 
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expression. Many complex and metabolic diseases, where the increase of pro-
survival factors and dysregulated enzymes may impact the well being of 
patients, could as well benefit from its usage. Even if its application is still in 
its infancy, two recent studies reported SINEUPs efficiency of modulating 
protein production in vivo, encouraging their future deployment as RNA 
drugs (101) (102). SINEUP technology has been tested in a medakafish 
model of microphthalmia with linear skin defects (MLS) syndrome, caused 
by mutations in players of the mitochondrial respiratory chain (MRC) 
including the subunit 7B of cytochrome c oxidase (COX) (101). SINEUP 
targeting the endogenous cox7B mRNA has been injected in MLS morphants 
resulting in restored MRC function and phenotype. Interestingly, SINEUP 
injection fully rescued microphthalmia and microcephaly in about 50% of 
embryos, whereas the injection of a control SINEUP did not result in 
amelioration of the phenotype by reinforcing validation of SINEUP 
specificity (101). SINEUP-based therapy, referred to as RNAe, has also been 
proposed by Longo and colleagues. Evidence of SINEUP activity has been 
reported in transgenic mice targeting RNAe antisense to the growth hormone 
gene, causing heavier body weight and longer body length compared to 




Friedreich’s ataxia (FRDA) was firstly described by Dr. Nicholaus Friedreich in 
1863 as inherited ataxia involving spinal cord, peripheral nerves and cerebellum (103). 
The pathogenic mutation in FRDA is a guanidine-adenine-adenine (32) trinucleotide 
repeats expansion on chromosome 9q13 (104) that leads to transcriptional silencing of 
the frataxin gene (FXN) (4). Broadly, the decrease of FXN transcription perturbs iron 
homeostasis promoting cardio- and neurodegeneration (105) (4). 
Clinical features 
Patients (75% affected individuals) typically show degeneration of large sensory 
neurons of the dorsal root ganglia, Betz pyramidal neurons of the cerebral cortex and 
lateral cortico-spinal and spinocerebellar tracts, as well as lesions in the dentate 
nucleus of the cerebellum (4). The main age of onset of symptoms is ten to fifteen 
(106). Within five years after, individuals exhibit lower-extremity weakness, 
diminished or absent joint-position, vibration sense distally, and dysartria. The latter, 
is generally of three type: mild dysarthria, hypernasality, and increased strained-
strangled vocal quality (107). Dysphagia, relates to oropharyngeal coordination, 
weakness and spasticity, is also common (92% of affected individuals) (108). 
In addition, non-neurological degeneration causes hypertrophic cardiomyopathy 
and increased incidence of diabetes mellitus. This occurs in up to 30% of patients (109) 
whereas impaired glucose tolerance is seen in up to an additional 49% (110) (111). 
Two thirds of affected individuals show increased interventricular septum thickness 
(112). Systolic dysfunction and left ventricular wall thickness appear as the disease 
progresses (113). Based on the ejection fraction, two main groups should be identified. 
The first, approximately represent 80% of affected individuals, “low risk” group with 
a normal ejection fraction that even though declined, it remains into the normal range. 
The latter, “high risk” group, had a decrease ejection fraction into the abnormal range 
combined with high mortality rate. 
Neurodegenerative motor symptoms typically appear before adolescence with 
progressive gait instability and loss of coordination, while the cardiac impairment 
usually occurs in the later stages of the disease (114). Atrial fibrillation and congestive 
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heart failure are the most common cause of mortality (115) at a mean age of 40 years 
(116). 
FRDA individuals with Late-Onset (LOFA - 26-39 years) and Very Late-Onset 
(VLOFA - after age 40 years), represent approximately 15% of patients (117) (118). 
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Genetic basis of the disease 
FXN gene 
Frataxin is a small highly conserved acidic protein (≈ 17 kDa) (NP_000135.2), 
encoded via a major transcript (NM_000144.4) in the nucleus, expressed in the 
cytoplasm and imported in the mitochondrion through an import signal in the N-
terminus. This transcript is composed of five exons (1-5a) and encodes for 210-amino 
acid protein (isoform A). Alternative splicing produces minor transcripts with exon 5b 
instead of 5a, in the presence of an additional non-coding exon 6 that may or may not 
be present (isoform B and isoform B1 respectively) (Figure 13) (119). 
 
Figure 13 - Schematic representation of the genomic structure of FXN on the long arm of chromosome 9 
(position 9q13) with centromeric (9qc) to telomeric (9qt) orientation indicated. Two alternate transcripts are 
shown. Adapted from (120). 
Two major transcription start sites (57) were identified in the FXN gene: TSS1 
(119) and TSS2 (121) respectively 221bp and 62bp upstream of the ATG translation 
start site. The region in-between is thought to be TATA-less downstream promoter, 
transcription factors binding sites (122), as well as insulator protein CCCTC-binding 




GAA triplet repeat expansion 
The human FXN locus is located on chromosome 9q21 and contains normally 
from 10 to 66 GAA-triplet repeats within the first intron, whereas FRDA patients carry 
an intronic homozygous expansion of natural tandem repeats up to 1700 triplets (119). 
In a small percentage of cases, however, patients are compound heterozygotes for 
GAA expansion on one FXN allele and a small insertion, deletion or point mutation in 
FXN open reading frame on the other (124). In contrast, in rare instances, GAA repeats 
are interrupted by other nucleotides usually closed to the 3’ end of the repeat tract. 
Such “rare interrupted FNX alleles” may be associated with a later onset of the disease 
(125). All pathogenic variants result in a loss of frataxin function. Apart from (32) n 
repeats, a number of repetitive DNA element have been identified at FXN locus, 
including L2 (LINE) (126), Alu (SINE), and MIRb (119) (127). Their precise function 
in FXN regulation is still not known. 
 
Figure 14 – Graphical rappresentation of 5’ end of the frataxin gene. Minimal promoter, exon 1 and the 
promoter proximal end of intron 1 are shown. TSS1 and TSS2 refer to transcription start sites described in two 
different studies. The positions of various interspersed repeated sequences are indicated by the rectangles 
outlined with black dashed lines. The dotted black arrow indicates the estimated extent of the FXN antisense 
transcript-1 (FAST-1) transcript based on nested PCR. Arrows indicate the location of the binding sites for 
serum response factor (SRF), activator protein 2 (AP2), CCCTC-binding factor (CTCF), an early growth 
response protein 3 (EGR3)-like factor and an E-box binding protein which have been shown to be positive 
regulators of FXN expression. From (121). 
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Deficiency of FXN transcript levels and ultimately of frataxin protein results in a 
secondary deficiency of iron-sulfur cluster-containing enzymes, mislocalization of 
cellular iron, and increased sensitivity to oxidative stress, and therefore an impaired 
mitochondrial respiratory function. 
Despite the clinical outcome is not precisely predictable based on genotype, it 
has been demonstrated that longer hyperexpansions result in a more severe phenotype 
with an earlier onset and faster progression (128) (129) (130) (131). This inverse 
correlation it is clear even from both LOFA (<500 repeats) and VLOFA (<300 repeats) 
individuals (132) (133). Moreover, cardiomyopathy is more present in patient with 
large expansions (130) (128) (129,134) (135). 
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FXN transcription inhibition 
Although the mechanism by which GAA triplet repeat expansion leads to FXN 
silencing is still not precisely understood, two main hypotheses has been proposed.  
Firstly, GAA repeat expansions may impair FXN transcription by inducing the 
formation of triple helical DNA structures (sticky DNA) (136) or persistent 
DNA/RNA hybrids (R-loops) (137) that infers with elongation. On the other hand, 
epigenetic silencing, via repressive chromatin formation in the sequence flanking the 
expanded GAA region or near the FXN promoter, may interfere with both 
transcriptional initiation and elongation (138) (123) (139) (121) (140) (141,142) (143) 
(Figure 15). 
 
Figure 15 - Models of FXN gene silencing in FRDA. (A) Unaffected individuals, contain active histone marks 
of gene transcription initiation and elongation at the FXN promoter and intron 1 regions. (B) Potential silencing 
mechanisms in FRDA patients: (i) the GAA•TTC repeat may adopt abnormal non-B DNA structures (triplexes) 
or DNA•RNA hybrid structures (R loops), which impede the process of RNA polymerase and thus reduce FXN 
gene transcription, (57) increased levels of DNA methylation and HP1 and significant enrichment of repressive 
histone marks at the FXN gene trigger heterochromatin formation that may lead to more pronounced FXN gene 
silencing (144)  
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Antisense RNA transcripts are known to play a crucial role in gene regulation, 
and have previously associated with TNR expansion disease e.g. Huntington disease 
(145) (123). Moreover, the CCCTC-binding factor (CTCF) protein has a fundamental 
role of preventing DNA methylation spreading. Bidichandani and colleagues found 
increased levels of frataxin antisense transcript (FAST-1) in patient-derived cell lines 
associated to depleted CTCF binding site, suggesting involvement of these factor in 
heterochromatin formation and perhaps in FXN silencing (Figure 16) (144) (123) 
(138). However, since DNA methylation at the CTCF-binding site within the 5’ UTR 
region of FXN gene has not been detected (123) (138), further evidences are needed, 
since they likely should be highly relevant for an epigenetic-based therapy for FRDA. 
 
Figure 16 - (A) Unaffected: normal-sized GAA repeat (B) FRDA: GAA repeat expansion. Gray boxes represent 
regions of disease-associated DNA methylation and hydroxymethylation. Arrow marks represent the directions 
and levels of transcription for FXN and FAST-1. Blue bars represent exons of the FXN gene. Red triangles 
indicate GAA repeats within intron 1 of the FXN gene. From (144) (123) (138). 
Lastly, based on the ability of repeats to bind splicing factors, it has been 
suggested that FXN mRNA deficit results from an altered splicing (146). Reduced 
splicing is related to intron length in yeast, where the largest one is <1 Kb (147). 
However, many efficiently spliced human introns are much longer, including normal 
FXN intron 1 (11 Kb). Since a very unstable splice isoform has been shown in FRDA 
cells (117) (148), this issue is still unsolved. 
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Epigenetic changes associated with FRDA 
DNA methylation and hydroxymethylation, post-traslational histone 
modification, chromatin remodelling, and non-coding RNA effects are laid down in 
epigenetic mechanisms that produce effects on gene expression without involving 
changes in the primary DNA sequence. A potential involvement in FRDA disease was 
firstly suggested by heterochromatin-sensitive cell surface reporter gene silencing in 
transgenic mice by position effect variegation (PEV) mediated by a nearby long GAA 
expansion (149). Further studies have subsequently identified epigenetic changes, 
which may be involved in FXN gene silencing in FRDA (138) (140) (148) (121) (123) 
(139) (150) (151) (152) (153) (154). 
Initial investigation of DNA methylation within FXN gene revealed 
hypermethylation of three out of fifteen specific CpG sites up-stream the expansion in 
patient-derived lymphoblasts compared to healthy controls (151). Sandi and 
colleagues corroborated previous finding in FRDA patient autopsy brain, heart, and 
cerebellum tissues (138). Moreover, direct correlation between expansion length and 
the extend of DNA methylation in FRDA patient blood samples has also be found. 
Post-translational histone modification is associated with heterochromatin 
formation and gene silencing, particularly histone hypoacetilation (e.g. H3K9) and 
increased histone methylation (e.g. H3K9me2, H3K9me3, HeK27me3, and 
H4K20me3). Modification at the FXN locus were first identified by Gottesfeld and 
colleagues by identifying increased H3K9me2 and H3K9me3 in FRDA 
lymphoblastoid cells (139). Further studies reported changed histone modification at 
the FXN 5’UTR region, FXN promoter, up- and down-stream GAA repeat expansion 
in FRDA patient and mouse models (138) (123) (150) (151). Recent studies have 
shown decreased level of H3K9me3, HeK27me3, and H4K20me3 at the up- and 
down-stream GAA repeats expanded region indicating transcription elongation 
impairment. Moreover, unchanged modification at the promoter region has recently 
been reported. This indicates that an elongation defect occurs rather than an early 
transcription initiation deficit (121) (148) (153). 
In summary, frataxin expression deficiency in FRDA is mainly caused by GAA 




Frataxins are small proteins highly conserved from bacteria to mammals, mainly, 
but not exclusively, confined inside the mitochondrial matrix (155) (156) (157). Musco 
and colleagues determined the structure of human frataxin isoform A (158), as well as 
the E. coli homologue CyaY and the mature form yeast homologue Yfh1. All these 
structures shared similar fold reflecting high degree of sequence conservation, thus 
suggesting a common function. As confirmed by De-Phaganon end colleagues, 
frataxin structure consists in six-stranded β-antiparallel sheet, flanked by N- and C-
terminal α-helices, with no main surface cavity (Figure 17) (159). Residues on the α-
helices are negatively charged, which can be responsible of iron-binding. Unlikely, β-




Figure 17 - Structure of frataxin. Compact αβ sandwich, with α helices in turquoise and β strands in green. 
Strands β1–β5 form a flat antiparallel β sheet that interacts with the two helices, α1 and α2. The two helices are 
nearly parallel to each other and to the plane of the large β sheet. A second, smaller β sheet is formed by the C 




Encoded in the nucleus, human frataxin protein is synthesized in the cytoplasm 
as 210 amino acid precursor (23 kDa). The N-terminal portion contains mitochondrial 
import sequence (41 amino acid long) that directs its transport into the mitochondrial 
matrix (155) (156). Here, it is converted into the functional mature form through the 
two-step proteolytic maturation mediated by mitochondrial processing peptidase 
(MPP) enzymes. An initial cleavage, within Gly41 and Leu42, generates the 
intermediate form (iFXN; 19 kDa) by removing the transit peptide  (160). However, 
longer intermediate form may be produced in some normal cells when the normal 
processing is impaired (161). 
 The second site of cleavage has longly been controversial (162) (160) (163) 
(164). Based on the putative second site, three mature forms have been proposed by 
different in vitro studies: m56-FXN (Ala55 and Ser56; 17 kDa) (162), m81-FXN (Lys80 
and Ser81; 14.2 kDa) (160), and m78-FXN (Asn77 and Leu78; 14.5 kDa) (163). 
Moreover, both m81-FXN and m78-FXN has been reported as degradation products (d-
FXN) in human heart extracts (165) (163) (158) (162).  In addition, further confusion 
turned out from the abnormal mobility observed on SDS-PAGE for yeast, murine, and 
human frataxin, attributed to its acidic nature (164) (166) (162) (167). Lastly, 
Schmucker and colleagues provided greater clarity that the endogenous mature 
frataxin corresponds to m81-FXN, supporting previous results (160). Most importantly, 
they demonstrated m81-FXN capability to rescue the survival of deficient murine 
fibroblasts. (Figure 18) (168). 
The two-step processing by MPP (mitochondrial processing peptidase) should 
also have regulatory function, since it has been demonstrated in rat liver mitochondria 
that the second cleavage is finely tuned. While the precursor is rapidly cleaved, the 




Figure 18 – Schematic representation of the different forms of frataxin. The precursor is targeted to the 
mitochondrion and undergoes a two-step maturation process. The intermediate and the three described mature 
forms are represented. The conserved globular domain which starts at amino acid 90 is indicated by the gray 
area. Scheme is not drown in scale. 
The mystery of frataxin cellular function 
Frataxin down-regulation causes deregulation of the mitochondrial iron 
metabolism pathway and subsequent mitochondrial iron loading. Three major 
pathways are involved: iron-sulfur cluster (ISC) biosynthesis, haem biogenesis and 
mitochondrial iron storage (105). The various proposed molecular functions derive 
from the capability of the protein to bind iron (Figure 19). 
 
Figure 19 - Iron binding. Adjacent frataxin molecules are colored green and yellow. Iron, depicted as a red 
sphere, is coordinated to His-177. Distances in Å (dotted lines) are between the nucleus of iron and its closest 
neighbours. Adapted from (159). 
Initially, due to the observation of Yfh1 oligomers and multimers with 
ferroxidase activity in presence of an excess of iron, frataxin has been proposed as iron 











mediated oxidative stress resulting from toxic reactive oxygen species (ROS) and 
abnormal mitochondrial deposits (103). Some evidence suggests iron chaperone or 
“donor” function in iron-dependent reactios, such as ISC and heam biosynthesis. 
Related alternative hypothesis indicates frataxin as metabolic switch, shifting iron 
from one metabolic pathway (e.g. ISC biosynthesis) to another (e.g. heam 
biosynthesis) (169). Interestingly, CyaY may function as iron sensor inhibiting the rate 
of ISC biosynthesis in case of both high iron availability and low disposal of 
downstream ISC apo-receptor. The latter remains to be demonstrated in eukaryotes 
(170). 
In summary, although its primary function is still debated (171), mature frataxin 
is a key component of the iron-sulphur cluster (172) biosynthetic apparatus (173) (168) 
(174), which provides the essential cofactor to all ISC-dependent enzymes of the cell 
(175) (176). As consequence of insufficient FXN expression, defective ISC 
biosynthesis triggers a series of vicious cycles leading to deregulated intracellular iron 
homeostasis, impaired mitochondrial electron transport chain and higher sensitivity to 
trigger oxidant- and stress-induced cell death (177) (178) (179). Despite many studies, 
the rationale behind the impact of frataxin deficiency is still poorly understood. 
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Therapeutical approaches in FRDA: goals and objectives 
Numerous therapeutical approaches in FRDA are currently in various phases of 
development and testing, and may broadly be classified into two major categories: 
drugs aiming to treat typical FRDA manifestation and those intended to increase 
frataxin content (180) (181). As far as our interest on protein up-regulation, here only 
treatments aiming to up-regulate frataxin protein content and mRNA transcription will 
be presented. 
Erythropoietin (EPO) is a glycoprotein produced in the kidney as hypoxia 
response and it is currently accepted for chronic anemia treatment. Moreover, it has 
cyto-protective and tissue regeneration properties. Previous study reported that human 
erythropoietin raises the amount of frataxin protein without increasing FXN mRNA 
levels (182). The observed increase was hypothesized to be attributable to a post-
translational mechanism, as by influencing frataxin protein half-life (183). However, 
the exact pathway by which erythropoietin upregulates frataxin remains unknown and 
a role in protein translation process cannot be ruled out. 
Histon deacetylase (HDAC) inhibitors are chromatin-modifying enzymes, 
reported to revert FXN silencing by interfering with hypoacetylation and 
hypermethylation of histones, usually seen in association to GAA repeat expansion in 
FRDA (184) (185). Nicotinamide, also known as vitamin B3, treatment was associated 
with FXN mRNA and protein levels upregulation to levels seen in asymptomatic 
heterozygous carriers. However, adverse events were often encountered upon dose 
escalation, thus suggesting that dosage should be individually adjusted (181) (150). 
Similarly, RG2833, another HDAC inhibitor, up-regulates FXN mRNA, but it is 
poorly adsorbed in central nervous system. In addition, a possible conversion into a 
toxic metabolite led to the premature termination of its phase II trial (185). To date, a 
new generation of molecules is under development to enhance potency as well as to 
prevent formation of dangerous metabolites. 
Resveratrol is a natural polyphenol with antioxidant, anticancer, and 
neuroprotective properties and it was found to up-regulate frataxin in both FRDA 
patient-derived cells and mouse model (186). However, it presents several important 
side effects as well as delivery issues. 
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Interferon-γ is an endogenous cytokine involved in both immune response and 
iron redistribution upon viral infection (187) (188). It is a currently FDA-approved 
treatment for chronic granulomatous disease and severe malignant osteopetrosis (180). 
Interferon-γ has been reported to enhance FXN expression in FRDA fibroblasts as well 
as in dorsal root ganglia of mouse model, probably by enhancing transcription and or 
stabilizing FXN mRNA (189). However, several pilot studies in phase III trials showed 
no statistical significant differences between individuals taking interferon-γ and 
placebo. 
New promising approaches are represented by gene therapy, gene and protein 
modulation, and protein replacement.  
A novel delivery system, known as trans-activator transcription (57), represents 
an innovative delivery approach. TAT is short peptidic fragment able to reach multiple 
tissue and cellular organelles, including mitochondrion. A knock-out mice injection of 
engineered small fusion-protein (TAT-FXN) resulted in a prolonged life span (up to 
53% longer than untreated mice) and an improvement of cardiac function with 
increased heart rate, growth velocity, and cardiac output. Treated mice showed 
enhanced cardiac aconitase levels suggesting improvement in iron-sulfur dependent 
protein regulation (190). Therefore, exogenous protein replacement of missing 
frataxin represent a promising approach for therapeutic intervention in FRDA. Clinical 
trials are expected to begin within a few years. 
An analogous approach, recombinant FXN mRNA nanoparticles, avoiding naked 
mRNA degradation, was successfully delivered in mice, resulting in effective frataxin 
translation. However, further optimization is still required (191). 
The mechanism of frataxin degradation is not fully elucidated. Benini and 
colleagues recently identified RNF126 as selective E3 ligase responsible of frataxin 
ubiquitination and therefore degradation (192). Therefore, hopefully down-regulation 
of FXN breakdown should also represent a novel potential therapeutical approach. 
Recently, oligonucleotide-based approach has got off an auspicious start in RNA 
therapeutics with the latest FDA approval of nusinersen in Spinal Muscular Atrophy 
(SMA) (193) (194) (195). Even though the mechanism trigging FXN transcriptional 
silencing is still incompletely elucidated, chromatin modification it is well known to 
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elicit FXN expression repression. In FRDA the pathological expanded GGA triplet 
repeats could bind the complementary genomic DNA, resulting in the formation of R-
loops that infer with transcription. Oligonucleotides (synthetic duplex RNAs) targeting 
the expanded mRNA repetitive region, by obstructing interaction with genomic DNA 
result in frataxin up-regulation to normal levels (4-6fold increase) by normalizing FXN 
gene expression (3-4folds) in patient-derived cells. Employment of single-stranded 
locked nucleic acid (LNA) oligonucleotide has been also revealed effective. 
Lastly, oligonucleotides may be applied on antisense lncRNAs degradation 
(FAST-1), also responsible of FXN repression, if coupled with RNAse-H enzyme that 
catalyzes RNA cleavage and degradation (51) (196). 
Oligonucleotide-based strategy could theoretically be targeted also on 
downstream events, such as gene methylation as well as miRNAs suppression (120). 
To date, no clinical candidates have been defined, even though PGC1α and NRF2 
down-regulation have been recently proposed (180). 
Up to date, the most promising potential therapy to ameliorate or restore frataxin 
levels in patients is the gene therapy. The rescue of frataxin loss may be achieved either 
by gene editing or by the delivery of wild type FXN by intravenous administration of 
viral vectors. In the former case, CRISPR-Cas9 and related technology were 
successfully applied in mice (197) (198). In the latter, AAV9-frataxin injection 
reverses the functional features of cardiomyopathy when injected in pre-symtomatic - 
cardiac frataxin - knock-out mice. More importantly, same results have been reported 
with those experiencing heart failure (199). Moreover, increased frataxin expression 
reduces cardiac hypertrophy, and prolong life span when compared with untreated 
mice. However, the potential risk of over-replacement is still the major concern (200). 
In addition, infection with TALE (transcription activator-like effector) proteins 
coupled with a TAD (transcription activation domain) specifically directed at the 
human frataxin promoter leads to a 2fold increase in the expression of frataxin, both 
mature mRNA and protein content (201). However, immunological tolerance to 
specific proteins is still an open issue of this method. 
The serious risk of aberrant overexpression is shared by all above mentioned new 
promising strategies. Controversial results have been published on the effectiveness of 
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overexpression itself. While frataxin up-regulation shows evident phenotype 
amelioration in different disease models (200) (202) (203), it may even be toxic due 
to its disturbing effect on Fe-S biogenesis and increasing oxidative stress (204) (205). 
Taking advantage of the HEK-cFXN inducible model (206) effects of overexpression 
have been monitored over time. Surprisingly, it led to a prominent decreased ATP 
production and an even more pronounced oxidative stress (205). It is worth noting that 
negative outcomes refers to a healthy environment, since HEK cells normally produce 
frataxin. Indeed, Navarro and colleagues, observed deleterious effects at the 
biochemical, histological and behavioural levels in transgenic overexpressing flies, yet 
at the same time also indicated complete rescue of aconitase activity in knockdown 
flies’ mutants (204). Thus, the understanding of the exact amount of frataxin required 
to revert patient phenotypes without any side effects still remain a crucial unmet issue. 
These results may further strengthen the use of SINEUPs as potentially ideal 
therapeutic strategy to restore physiological levels. 
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MATERIAL AND METHODS 
OLIGONUCLEOTIDES 
The complete list of oligonucleotides used for cloning, quantitative real-time 
PCR experiments and lentivirus titration is included in Supplementary Information 
(Figure S1). 
CONSTRUCTS 
SINEUP-FXN were generated using pcDNA 3.1(-)- Δ5’-AS Uchl1 as backbone 
(82) lacking the region of overlap (BD) to Uchl1 and retaining AS Uchl1 ED. 
BDs were designed in antisense orientation to the most widely expressed human 
FXN mRNA, targeting the first or the second AUG, with longer or shorter overlapping 
region, following pairing roles of S/AS Uchl1 (82). Oligonucleotides were annealed 
and cloned into recipient plasmid.  
For the plasmid-driven expression of miniSINEUP-FXN, we constructed a DNA 
cassette containing the H1 RNA polymerase III promoter followed by the BDs of 
SINEUP-FXN of interest, the invSINEB2 of AS Uchl1 (95), and a minimal 
polyadenylation signal (207). The cassette was cloned into the AseI restriction site of 
pEGFP-C2 vector (Clontech), with the H1 promoter oriented in the opposite direction 
with respect to the CMV promoter.  The resulting family of plasmids is designed to 
constitutively express a miniSINEUP of interest and the enhanced Green Fluorescent 
Protein (EGFP) as a reporter,  and is renamed miniSINEUP_DUAL. 
All SINEUP and miniSINEUP-containing vectors were verified by sequencing. 
CELL LINES 
HEK 293T/17 were obtained from ATCC® (Cat. No. CRL-11268™) and 
maintained in culture with Dulbecco’s Modified Eagle Medium (DMEM) 
GlutaMAX™ Supplement (Gibco by Life Technologies, Cat. No. 41090-028) 
supplemented with 10% fetal bovine serum (Euroclone, Cat. No. ECS0180L) and 1% 
antibiotics (penicillin/streptomycin), as suggested by the vendor.  
 38 
SH-SY5Y cells were obtained from ATCC® (Cat. No. CRL-2266™) and 
maintained in culture with RPMI supplemented with GlutaMAX, 10% fetal bovine 
serum not inactivated (Euroclone, Cat. No. ECS0180L) and 1% antibiotics 
(penicillin/streptomycin). 
Human GM04078 fibroblasts, from a clinically affected FRDA patient 
homozygous for the GAA expansion in the FXN gene with alleles of approximately 
541 and 420 repeats, were obtained from NIGMS Human Genetic Repository, Coriell 
Institute for Medical Research (Camden, NJ, USA). Cells were maintained in culture 
with Minimum Essential Medium (41) HEPES, GlutaMAX™ Supplement (Gibco by 
Life Technologies, Cat. No. 42360024) supplemented with 15% fetal bovine serum 
heat inactivated (Euroclone, Cat. No. ECS0180L), 1% non-essential amino acids and 
1% antibiotics (penicillin/streptomycin). 
Human GM16214 lymphoblasts from a clinically affected FRDA patient 
homozygous for the GAA expansion in the FXN gene with alleles containing 
approximately 700 and 600 repeats and human GM16215 lymphoblasts from a 
clinically unaffected parent with only one allele containing 830 repeats (mother of 
affected GM16214), were obtained from NIGMS Human Genetic Repository, Coriell 
Institute for Medical Research (Camden, NJ, USA). Both cell lines were maintained 
in culture with RPMI 1640 Medium (Euroclone ECB9006) supplemented with 15% 
fetal bovine serum heat inactivated (Hyclone CHA1115L),100 U/mg 
penicillin/streptomycin (Euroclone ECB3001D) and 2 mM L-glutamine (Euroclone 
ECB3000D). 
TRANSFECTIONS 
HEK 293T/17 and SH-SY5Y cells were plated in 6 well-plates the day before 
transfection at 60% confluency (4x105 cells/well) and transfected with 4 µg of 
SINEUPs or miniSINEUPs encoding plasmids using Lipofectamine® 2000 
(Invitrogen™ by Life Technologies, Cat. No. 11668019) and following 
manufacturer’s instructions. Cells were collected 48 hours after transfection. RNA and 
protein were obtained from the same transfection in each replica. 
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RECOMBINANT LENTIVIRUS PRODUCTION AND TITRATION. 
Selected miniSINEUP-FXN were cloned into a TetON-controlled lentiviral 
vector, based on the pCCLsin.PPT.hPGK.EGFP.Wpre backbone (208). Recombinant 
third generation self-inactivating (SIN) lentiviruses were produced and titrated as 
previously described (208). Briefly, HEK 293T/17 cells were transfected using 
LipoD293™ DNA In Vitro Transfection Reagent (SignaGen Laboratories, Cat. No. 
SL100668-5) with the transfer vector plasmid plus three auxiliary plasmids (pMD2 
VSV.G; pMDLg/pRRE;  pRSV-REV). The conditioned medium was collected after 
24 and 48hs, filtered and ultra-centrifuged at 50000 RCF on a fixed angle rotor (JA 
25.50 Beckmann Coulter) for 165 min at 4°C. Viral pellets were resuspended in DPBS 
without BSA (Gibco, Cat. No. 14190250). miniSINEUP-expressing lentiviral particles 
were titrated by Real Time quantitative PCR after infection of HEK293T/17 cells. One 
end-point fluorescence-titrated lentivirus was included in each PCR titration session 
and PCR-titers were converted into fluorescence-equivalent titers throughout the 
study. 
INFECTION OF HUMAN FRDA FIBROBLASTS 
At least 8.5 *105 FRDA fibroblasts were plated onto a 100 mm plate with medium 
supplemented with Hexadimethrine bromide at a final concentration of 0.009 µg/ml 
and infected with the appropriate miniSINEUP-expressing lentiviral vector 
(multiplicity of infection, MOI 10) together with trans-activating lentiviral vector 
(MOI 10). Cells were treated with doxycycline (1 m g/ml) every 48 hours after 
transduction and collected after 4 days of treatment. RNA and proteins were obtained 
from the same infection in each replica. 
STABLE TRANSFECTIONS OF FRDA LYMPHOBLASTS 
FRDA GM16214 lymphoblasts were transfected by electroporation as already 
described (156). Briefly, 15x106 cells were incubated in 0.4 ml of RPMI 1640 for 10 
min on ice with 30 µg of pMiniSINEUP-FXN constructs or relative empty vector. 
After electroporation at 260 V/950 microfarads (Bio-Rad GenePulser II), cells were 
left 30 min on ice and resuspended in 5 ml of complete RPMI 1640 medium. After 4 
h, live cells were recovered by Lympholyte-Human (Cedarlane Laboratories) density 
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gradient centrifugation and re-plated. Stable transfectants were obtained from cultures 
in selection medium containing 600 µg /ml G418 (Sigma) for at least 15 days. 
ACONITASE ASSAYS 
Whole-cell extracts from GM16215 lymphoblasts, GM16214 lymphoblasts and 
GM16214 lymphoblasts stably expressing miniSINEUPs were prepared in ice-cold 
CelLytic M buffer (Sigma–Aldrich) supplemented with 2 mM sodium citrate and 
Complete EDTA-free protease inhibitor cocktail (Roche Diagnostic). 
Spectrophotometric aconitase assays were performed at 25°C with 100 µg of cell 
extracts using the BIOXYTECH Aconitase-340 Assay (OxisResearch 21041). 
Spectrophotometric citrate synthase activities were assessed at 25°C with 10 µg of cell 
extracts using the Citrate Synthase Assay Kit (Sigma–Aldrich CS0720). For the 
calculation of the activities, one unit of enzyme was expressed as the amount of protein 
that converted 1 µmol of substrate per minute at 25°C.  
WESTERN BLOT 
Transfected HEK 293T/17 and SH-SY5Y cells were washed twice and collected 
in PBS 1X. Cell pellets were directly lysed in 300 µL of Laemmli sample buffer, 
briefly sonicated, boiled and loaded 10-20 µl/each sample on 10-15% SDS-PAGE gel. 
Infected human FRDA fibroblasts were collected in PBS 1X. Cell pellets were 
dissolved in 100 µL of Laemmli sample buffer, briefly sonicated, boiled and loaded 
20 µl/each sample on 10-15% SDS-PAGE gel. 
Proteins were transferred to nitrocellulose membrane (Amersham™, Cat. No. 
GEH10600001) for 1 hour at 100V. Membranes were blocked with 3% Bovine Serum 
Albumin (SIGMA, Cat. No. A2058) in TBST 1X solution for 1 hour at room 
temperature and then incubated with primary antibodies. The following antibodies 
were used: anti-FXN 4µg/ml (Abcam, Cat. No. 18A5DB1) overnight at 4°C followed 
by 1-hour incubation at room temperature with horseradish peroxidase-conjugated 
goat anti-mouse antibody (DakoCytomation, Glostrup, Denmark), anti-β-Actin-
Peroxidase 1:20000 (SIGMA, Cat. No. A3854). Proteins of interest were visualized 
with the Amersham™ ECL™ Detection Reagents (GE Healthcare by SIGMA, Cat. No. 
RPN2105) or LiteAblot TURBO Extra-Sensitive Chemioluminescent Substrate 
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(EuroClone, Cat. No. EMP012001). Western blotting images were acquired using with 
Alliance LD2-77WL system (Uvitec, Cambridge) and band intensity was calculated 
using ImageJ software. 
FRDA lymphoblasts extracts were prepared in ice-cold lysis buffer (50 mM Tris-
HCl pH 7.5, 150 mM NaCl, 1% Igepal CA-630, 5 mM EDTA, 5 mM EGTA) 
supplemented with Complete Protease Inhibitor Cocktail (Roche Diagnostics). 
Lysates were clarified by centrifugation, supernatants were mixed with 10× Laemmli 
sample buffer and boiled for 5 min at 95°C. 50 µg of protein extracts were resolved by 
12% SDS-PAGE gels and transferred to 0.2 µM nitrocellulose membrane (Trans-Blot 
Turbo Transfer pack, Bio-Rad). Membranes were blocked with 5% non-fat dry milk 
in PBS/0.1% Tween 20 and incubated with the indicated primary and secondary 
antibodies: mAb anti-FXN (MAB-10876 Immunological Sciences), mAb anti-α-
tubulin (clone DM1A, Sigma-Aldrich) and secondary antibody horseradish peroxidase 
(HRP)-conjugated goat anti-mouse (Thermo Fisher Scientific). The immunoreactive 
bands were detected by enhanced chemiluminescence (ECL, GE Healthcare) and 
imaged with a ChemiDoc XRS system (Bio-Rad). Densitometric analysis was 
performed using ImageLab 5.2 software (Bio-Rad). 
RNA ISOLATION, REVERSE TRANSCRIPTION AND QUANTITATIVE RT-PCR 
Total RNA was extracted from cell pellets using TRIzol® Reagent (Thermo 
Fisher, Cat. No. 15596026) and following manufacturer’s instructions. 
For HEK 293T/17, SH-SY5Y and GM04078 fibroblasts, RNA samples were 
subjected to TURBO™ DNase (Invitrogen, Cat. No. AM1907) treatment, to avoid 
plasmid DNA contamination. A total of 1 µg of RNA was subjected to 
retrotranscription using iScript™cDNA Synthesis Kit (Bio-Rad, Cat. No. 1708890), 
according to manufacturer’s instructions. qRT-PCR was carried out using SYBR green 
fluorescent dye (iQ SYBR Green Super Mix, Bio-Rad, Cat. No. 1708884) and an 
iCycler IQ Real time PCR System (Bio-Rad). The reactions were performed on diluted 
cDNA (1:8). Human GAPDH was used as normalizing control in all qRT-PCR 
experiments. 
For GM16214 and GM16215 lymphoblasts, cDNA was prepared using the 
SuperScript VILO cDNA synthesis kit (Thermo Fisher). Levels of human FXN mRNA 
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and miniSINEUPs RNA expression were assessed by real-time qPCR using the 
StepOne Plus Instrument (Applied Biosystems), normalized with the control genes 
expression. The assays were performed using the TaqMan primers listed in Sup.Fig.1 
(Applied Biosystems). GUSB, GAPDH and ACT were used as control housekeeping 
genes. 
The amplified transcripts were quantified using the comparative Ct method and 
the differences in gene expression were presented as normalized fold expression with 
ΔΔCt method (209). 
STATISTICAL ANALYSIS 
In all experiments the significance of differences between groups was evaluated 
by unpaired t-test with Welch's correction, p<0.05 were considered significant. 




1. SYNTHETIC SINEUP-FXN: DESIGN AND SCREENING 
Since SINEUPs target the mRNA sequence around the starting AUG, the precise 
knowledge of the real sites of transcription initiation is crucial, especially in cells and 
tissues relevant for the gene of interest and its associated disease. In our experience, 
we have found that the annotation of the reference sequence is often not representative 
of the cell-type-specific usage of transcription start sites (TSSs) and of 5'UTRs in 
endogenous mRNAs. To build FXN-specific SINEUPs, we interrogated FANTOM5 
collection of Cap Analysis of Gene Expression (CAGE) datasets, which represents the 
widest catalogue of annotated promoters and TSSs in mammalian samples (57). Using 
the Zenbu Genome Browser Tool for data visualization (210), we monitored TSS 
usage at the human FXN locus with a specific focus on human cells lines and tissues 
relevant for FRDA (Figure 20). 
 
Figure 201 – FXN locus view. ZENBU genome browser view of FXN locus showing FXN alternative TSS 
usage (TSS1, TSS2 and TSS3) in FANTOM5 samples and selected libraries. FXN reference sequences and 
Gencode annotated transcripts are indicated. The genomic position of the GAA triplet.  
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Unexpectedly, we found that the annotated reference sequences are poorly 
representative in human samples. Rather, at least two additional variants (TSS1 and 
TSS2) of human FXN mRNA exist that are positioned more closely to the initiating 
AUG and are supported by “robust” statistical definition of promoters in FANTOM5. 
The use of these alternative TSSs finds further confirmation in the Gencode catalogue 
of transcripts (ENST00000396366, ENST00000498653) (Figure 20). 
Based on TSS analysis, we designed FXN-specific SINEUPs (SINEUP-FXN) in 
antisense orientation to the most widely expressed variant of human FXN mRNA and 
following the pairing rules of S/AS Uchl1 (82). BDs were initially designed according 
to the canonical -40/+32 anatomy (95) and its shortest -40/+4 BD variant (211) (100). 
Although FXN mRNA has a very short 5’ UTRs, we included the -40 versions of 
SINEUPs to investigate whether extra sequences at the 5’ of the overlapping region 
could influence SINEUP activity. We then generated additional SINEUP-FXN by 
trimming BD sequences at both extremes, following a strategy previously used to 
optimize SINEUPs for overexpressed mRNAs but not yet tested for endogenous genes. 
Finally, since another methionine (M76) is positioned in frame in the second exon after 
the GAA-triplets repeat, we designed three additional BDs overlapping this sequence, 
immediately after or across the exon I/exon II boundary (Figure 21). 
 
 
Figure 21. Scheme of human FXN gene (5’ end) and BDs design of synthetic SINEUP-FXN. 
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Each BD variant was combined with the ED of the natural AS Uchl1 that so far 
represents the most potent translational activation domain for SINEUPs (Figure 22). 
To screen the activity of SINEUP-FXN, we took advantage of HEK 293T/17 cells 
which own the same TSSs of cells relevant for the pathology and have been proven to 
support SINEUP activity of a variety of SINEUPs targeting endogenous genes (95) 
(unpublished results). 
 
Figure 22 - Schematic representation of SINEUPs functional domains. The binding domain (overlap) 
provides SINEUP specificity and is in antisense orientation to the sense protein-coding mRNA (Target). The 
inverted SINEB2 element (invB2) is the effector domain (blue) and confers enhancement of protein synthesis. 
HEK 293T/17 cells were transfected with SINEUP-FXN (+SINEUP) or an empty 
control vector (-SINEUP). SINEUP activity was estimated as fold changes in protein 
levels in +SINEUP compared to –SINEUP conditions by western blotting (Figure 
23/a). qRT-PCR quantification of FXN mRNA was carried out to confirm SINEUPs 
act at post-transcriptional levels (Figure 23b). 
We found that SINEUP activity varies significantly according to the overlapping 
region. When SINEUP-FXN were designed around the initiating AUG as transcribed 
from both TSS1 and TSS2 and maintaining extra sequences at the 5’ end, we found 
that the activity is regulated by the length of overlap to the coding sequence (CDS). In 
particular, the canonical configuration of -40/+32 showed no effects on frataxin levels 
(data not shown). Instead, BDs with minimal (-40/+4) or no (-40/+0) overlap to the 
CDS induced up-regulation of mature frataxin in the range of 1.4-fold. Minimal up-
regulation was also obtained with SINEUPs targeting 5’UTRs from TSS1, albeit with 
some variability. When the overlapping region corresponds exactly to the 5’UTR from 
TSS2, as it is the case for -14/+0 and -14/+4 configurations, SINEUPs reached the 
highest potency (1.7- to 2-fold increase). 
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When BD was designed at -40/+4 (exon 2) and -10/-75/+4 (exon1-exon2) relative 
to internal in frame M76-AUG, we could not measure any increment in frataxin protein 
relative to controls. Instead, when the BD did not overlap the M76-AUG sequence but 
retained a complementarity to its preceding regions, as in the -40/+0 (M76) 
configuration, it generated a SINEUP that could substantially up-regulate frataxin up 
to 1.5-fold (Figure 23a) 
In summary, we successfully designed synthetic SINEUPs able to increase the 
quantity of frataxin protein with no effects on its mRNA levels (Figure 23b). SINEUP-




Figure 23 – SINEUP-fxn screening a) SINEUP-FXN variants were screened in HEK 293T/17 cell line. Control 
cells were transfected with empty vector. Protein levels were analyzed by western blot with anti-FXN antibody 
and SINEUP activity was calculated as increase in protein quantities relative to empty control samples (fold 
changes are shown). Summary of data on SINEUP activity (bottom), as frataxin protein quantities in 
HEK293T/17 cells. Data indicate mean ± SEM and are representative of four independent experiments. p values 
are calculated by unpaired t-test with Welch’s correction. *, p<0,05; **, p<0,01, ***, p<0,001; ns, non-
significant; b) RNA levels were analyzed by qRT- PCR with target-specific and SINEUP primers, respectively. 
In all conditions, FXN mRNA quantities were stable (ns, p > 0.05). 
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2. SYNTHETIC MINISINEUP-FXN ARE ACTIVE IN VITRO 
Synthetic SINEUPs derived from natural AS Uchl1 RNA are about 1200 
nucleotides long. For their potential usage as RNA therapeutics, shorter functional 
molecules retaining SINEUP translation enhancement activity are needed. Therefore, 
each BD variant of the most effective SINEUP-FXN was combined exclusively with 
the invSINEB2 (ED) sequence, producing ≈250 nucleotides long transcripts 
(miniSINEUP-FXN) (Figure 24). Four different BDs were selected (-40/+0, -14/+4, 
14/+0 on M1 and -40/+0 on M76), covering various anatomies of overlap to FXN 
mRNA. 
 
Figure 24 - Schematic representation of miniSINEUPs functional domains and design. 
miniSINEUPs were then tested in HEK293T/17 cells as before. We found that 
SINEUP miniaturization did not alter the activity of the selected molecules towards 
endogenous frataxin (Figure 25), strongly supporting the modularity of SINEUPs. As 
one of the prominent FRDA phenotypes involves the central nervous system, we 
monitored miniSINEUP-FXN in human neuroblastoma SH-SY5Y cell line confirming 
their activities (data not shown). Moreover, to asses the specificity we performed BD 
blast analysis that showed three different miniSINEUPs off-targets, with different 
degrees of confidence. By westerblot analysis, extracts derived from replicas taken 
into account for the validation were tested for those off-targets, resulting in any protein 
perturbation as a result of putative unspecific binding (Figure S2). 
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Altogether, miniSINEUPs promoted protein induction consistently in the range 
of 1.4- to 2.0-fold, proving that miniSINEUP-FXN retain the same mechanism and 
efficiency of their full-length counterpart with the advantage of being shorter (Figure 
25a). 
 
Figure 25 - miniSINEUP-FXN activity in HEK293T/17 cell line. a)Protein levels were analyzed by western 
blot with anti-FXN antibody and SINEUP activity was calculated as increase in protein levels relative to empty 
control samples (fold changes are shown). Summary of data on SINEUP activity (bottom), as frataxin protein 
quantities in HEK293T/17 cells. Data indicate mean ± SEM and are representative of four independent 
experiments. p values are calculated by unpaired t-test with Welch’s correction. *, p<0,05; **, p<0,01, ***, 
p<0,001; b) RNA levels (bottom) were analyzed by qRT-PCR with target-specific and SINEUP primers, 
respectively. In all conditions, FXN mRNA quantities were stable (ns, p>0.05). 
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3. PROTEIN RESCUE IN FRDA-DERIVED FIBROBLASTS 
FRDA-derived cells represent the most relevant cellular model to test therapeutic 
strategies for patients, as they carry the complete FXN locus together with pathogenic 
GAA-triplet repeat expansions (212). The most promising miniSINEUP-FXN were 
cloned into a lentiviral expression vector, in-between the doxycycline-controlled TREt 
promoter and BGHpA to build inducible recombinant lentiviral particles (LVs 
miniSINEUP-FXN). We took advantage of LVs, paired with a constitutive rtTA2S-
M2 trans-activator, to drive delayed and TetON-controlled expression of 
miniSINEUP-FXN. An additional virus, lacking miniSINEUPs, was used as a 
negative control. To optimize induction conditions, lentiviral particles were 
transduced in SH-SY5Y cells, and miniSINEUP expression and frataxin levels were 
measured at different time points, following a single or a double doxycycline (Doxo) 
induction (Figure S3a) We found that a single Doxo stimulation, combined with tests 
at 48 hours, was not sufficient to trigger SINEUP-mediated increase in frataxin 
quantities. Instead, a double treatment protocol was crucial to promote protein 
induction (Figure S3b). We then applied the double-Doxo protocol to infected FRDA 
cells as a proof of principle that SINEUPs could be exploited in a pathological context. 
Among available patients-derived cells, we selected primary FRDA fibroblasts 
(GM04078) carrying a hyper-expansion of about 541 repeats on one allele and 420 
repeats on the other, and showing an intermediate phenotype. All LV-miniSINEUPs 
led to an increase in frataxin quantities in the range of 1.6 to 2.1 fold (Figure 26a), as 
observed in cells with physiological numbers of GAA repeats. Importantly, the 
position of SINEUP BD relative to the GAA expansion and the presence of the 
pathological expansion itself did not interfere with the observed protein increase in 
patients’ cells. Considering that GM04078 cells show reduced levels of frataxin, 
averaging around 40% when compared to age- or sex-matched healthy-derived cells 




Figure 26 - Protein rescue in frda-derived fibroblasts. a) Primary fibroblasts derived from a FRDA patient 
(GM04078) were infected with inducible lentiviral vectors driving miniSINEUP-FXN expression. Control cells 
were infected with empty virus. Protein levels were analyzed by western blot with anti-FXN antibody and 
SINEUP activity was calculated as increase in protein levels relative to empty control samples (fold changes are 
shown). Summary of the effects of miniSINEUPs on frataxin protein quantities in FRDA cells. Data indicate 
mean ± SEM and are representative of four independent experiments. p values are calculated by unpaired t-test 
with Welch’s correction. *, p<0,05; **, p<0,01, ***, p<0,001; b) RNA levels (bottom) were analyzed by qRT-
PCR with target-specific and SINEUP primers, respectively. In all conditions, FXN mRNA quantities were 






















4. THERAPEUTICAL PROTEIN RESCUE IN FRDA-DERIVED 
LYMPHOBLASTS 
The ability of miniSINEUP-FXN to up-regulate endogenous frataxin levels in 
patient’s fibroblasts prompted us to evaluate their therapeutic potential in a different 
FRDA cellular model. To this purpose, we employed FRDA-derived lymphoblasts, 
which carry the pathogenic expansion of GAA repeats and show reduced levels of the 
protein when compared to controls. 
Frataxin-deficient lymphoblasts derived from a FRDA patient (GM16214) were 
stably transfected either with the miniSINEUP-FXN targeting the initiating AUG (BD 
-40/+0 on M1) or an empty vector as negative control. Following antibiotic selection, 
independent clonal subpopulations were monitored by western blot (Figure 27a) and 
real-time PCR analysis (Figure 27b) Frataxin protein levels were evaluated in whole 
cell extracts from different clones and compared to untransfected lymphoblasts. As 
expected, extracts from FRDA cells showed a significant deficit of FXN expression 
with respect to control lymphoblasts derived from the healthy heterozygous patient’s 
mother. Analysis of independent miniSINEUP clones revealed a strong rescue of 
frataxin levels while negative control transfectants showed no significative change. In 
particular, we observed an upregulation ranging from 1.5- to 3.8-fold when compared 
to negative controls (Figure 27a). FXN mRNA expression was quite similar in FRDA 
patient cells, negative control clones and miniSINEUP-FXN clones, confirming their 
post-transcriptional mode of action (Figure 27b). Next, we investigated whether a 
miniSINEUP-FXN targeting the AUG downstream GAA expansions (BD -40/+0 on 
M76) could exert the same activity in these cells. To this purpose, we generated new 
stably transfected FRDA cells. As shown in Fig. 5a, this miniSINEUP-FXN was able 
to increase frataxin protein levels from 1.6- to 2.3-fold (Figure 27a). According to the 
translational mechanism, levels of FXN mRNA never showed significant changes. 
Collectively, data indicate that each miniSINEUP-FXN variant restored physiological 
levels of frataxin protein in FRDA-derived cells.  
 53 
 
Figure 27 - Therapeutical protein rescue in frda-derived lymphoblasts. Lymphoblasts derived from a FRDA 
patient (GM16214) were stably transfected with miniSINEUP-FXN constructs targeting the M1 AUG (-40/+0) 
or the M76 AUG (-40/+0). Control cells were stably transfected with empty vector. a) Upper panel: 
representative western blot analysis with anti-FXN antibody shows protein levels in GM16214 cells (FRDA), 
GM16215 cells (Healthy) and different FRDA clones transfected with empty vector (-), miniSINEUP-FXN M1 
(-40/+0) or M76 (-40/+0). Frataxin fold changes are relative to untransfected FRDA cells. Lower panel: 
summary of frataxin protein levels in untransfected and transfected cells. Data indicate mean ± SEM from at 
least four independent experiments. p values are calculated by unpaired t-test with Welch’s correction (**, 
p<0,01, ***, p<0,001). b) RNA levels were analyzed by qRT-PCR in untransfected and transfected cells 
described in (a). Left panel: FXN mRNA quantitation. Right panel: SINEUP RNA quantitation. In all conditions 
referring to FRDA cells, FXN mRNA quantities were stable (ns, p > 0.05). 
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5. FUNCTIONAL RESCUE OF DISEASE-ASSOCIATED PHENOTYPE 
As previously reported by several studies, frataxin-deficient cells are primarily 
affected by defective ISC biosynthesis. Accordingly, insufficient frataxin levels 
trigger a typical loss in the activity of aconitases, two different ISC-dependent 
enzymes located in mitochondrial and cytosolic compartments. To assess the 
functional impact of SINEUPs, aconitase activity was chosen as a functional readout 
of restoring frataxin physiological levels on the above-described FRDA stable 
transfectants. To evaluate the status of aconitases, enzyme activity was monitored in 
total lysates from miniSINEUP-FXN clones and untrasfected lymphoblasts by 
spectrophotometric assays. Extracts from these FRDA-derived cells exhibited a loss 
of aconitase activity close to 50% when compared to healthy-derived cells from the 
patient’s parent. Total aconitase activity was strongly rescued in FRDA lymphoblasts 
stably expressing miniSINEUP-FXN targeting the initiating AUG (BD -40/+0 on M1) 
while it was not restored in negative control cells. Furthermore, the deficit was also 
rescued in cells expressing the miniSINEUP-FXN variant, which targets internal AUG 
(BD -40/+0 on M76) and is capable as well to increase mature frataxin quantities 
(Figure 28a) Measured as a control, activity of citrate synthase, the Krebs cycle 
enzyme catalyzing the preceding step respect to aconitase, but lacking ISC, did not 
show significant fluctuations in assayed extracts (Figure 28b). These results 
demonstrate the rescue of the major disease-associated phenotype in cells derived from 
an FRDA patient. Altogether, our data prove that a treatment with miniSINEUPs 
targeting frataxin achieved protein physiological levels and a consistent rescue of 
pathophysiological defects in FRDA-derived cells. 
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Figure 28 – Aconitase Activity Assay. Enzyme assays on lymphoblasts derived from a FRDA patient 
(GM16214) stably transfected with miniSINEUP-FXN constructs targeting the M1 AUG (-40/+0) or the M76 
AUG (-40/+0). Control cells were stably transfected with empty vector. a) Aconitase assay shows enzyme 
activity in GM16214 cells (FRDA), GM16215 cells (Healthy) and FRDA clones transfected with empty vector 
(-), miniSINEUP-FXN M1 (-40/+0) or M76 (-40/+0). b) Citrate Synthase assay shows enzyme activity in 
untransfected and transfected cells described in (a). All data indicate mean ± SEM from at least four independent 
experiments. p values are calculated by unpaired t-test with Welch’s correction (*, p<0,05; **, p<0,01; ***, 
p<0,001; ns, p > 0.05).  
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DISCUSSION 
FRDA is a rare genetic disorder caused by an insufficient quantity of frataxin 
protein. Since its discovery in 1996, the understanding of frataxin functions has grown 
rapidly (171). However, no effective therapy is currently available to the patients (214). 
The main root of the pathology is the impaired transcription of FXN gene as result of 
GAA repeat expansion. Disease onset, severity and rate of progression are strictly 
dependent on the length of repeat expansion and ultimately frataxin levels. 
Homozygous GAA expansion leads to a pronounced drop in protein levels, up to only 
20-30% compared to non-carrier’s healthy individuals. Interestingly, heterozygous 
carriers are clinically healthy with protein levels ranging from 50% to 70% of controls 
(215,216). 
During the last decade RNA-based therapy had a burst of interest because of both 
the high selectivity and the potential scalability to a large repertory of untreatable 
human diseases. Most RNA therapeutic molecules are inhibitory RNAs and have been 
developed to down-regulate expression of pathogenic genes. Among them, Small 
Inhibitory RNAs (siRNAs) and Anti-Sense Oligonucleotides (ASOs) are currently 
being tested in clinical trials for different disorders. Despite a huge improvement in 
terms of RNA stabilization, off-target effects reduction and on-target activity 
maximization, delivery still requires to be optimized. To this purpose, advanced carrier 
nanoparticles and new-generation adenoviral-associated vectors may eventually lead 
to new efficient target-specific drugs delivery. Furthermore, nucleic acid-based drugs 
can be directly delivered into the brain by intratechal injection. Thus, among others, a 
modified ASO targeting ISS-N1 (Intronic Splicing Silencer N1) has been successfully 
administrated in human CNS by intratechal injection (217) and it has been recently 
approved by FDA for spinal muscular atrophy treatment. 
On the other hand, a large group of diseases would strongly benefit from 
transcriptional- or translation-stimulating drugs able to rescue physiological levels of 
a specific target protein (12). 
Currently, there are no therapies to treat the disease or prevent its progression. 
The most promising approaches point to restore sufficient frataxin levels (180), mostly 
by enhancing FXN transcription. Among them, IFN-γ (189) and dyclonine (97) have 
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been identified as encouraging candidates by drug repositioning programs. Synthetic 
histone deacetylase (HDAC) inhibitors have been described to increase FXN mRNA 
in FRDA-derived cells and in FRDA animal models (139) (218). More recently, 
synthetic nucleic acids were successfully employed targeting GAA repeats, acting as 
R-loops inhibitors (51). Moreover, polyamide-based transcription factors capable of 
binding GAA microsatellite were developed (219). Interestingly, protein replacement 
therapy, based on TAT-frataxin delivery (190), and frataxin degradation prevention, 
by a class of ubiquitin-competing small molecules (220), have been recently proposed 
as potential treatments targeting the frataxin polipeptide. Finally, an effective gene 
replacement strategy in the FRDA mouse model opened new opportunities for gene 
therapy in the future (199). 
Recently, gene-specific transcriptional activating RNAs (RNAa) (1) and non-
degradative ASOs (2) have been employed to increase the expression of selected genes. 
As insufficient amounts of FXN mRNA are responsible for frataxin deficiency, this 
latter class of activating RNAs should be beneficial. It has been demonstrated that GAA 
expansion leads to DNA-RNA hybrid (R-loop) formation in vitro (221) (222) and 
inhibition of transcription due to RNA polymerase arrest. Interestingly, ASOs targeting 
FXN GAA repeat and R-loop structure are able to increase FXN mRNA in different 
FRDA patient-derived cell lines (223). 
Almost all investigated molecules capable of elevating frataxin are currently 
aimed at increasing FXN transcription. In this context, SINEUPs represent a new and 
alternative approach to increase FXN expression, acting at post-transcriptional level. 
SINEUP-FXN are in antisense orientation 5’ head-to-head to the most widely 
expressed FXN mRNA. Starting from canonical -40/+32 on M1, we screened different 
BDs to identify the shortest ones, while maintaining specificity. Each variant was 
combined with the ED of AS Uchl1 that so far represents the most potent translational 
activation domain for SINEUPs. Here we show that synthetic SINEUPs against the 
endogenous mRNA of FXN are able to increase its protein synthesis. Furthermore, we 
demonstrate BD’s flexibility designing them around the initiating AUG of target 
mRNA as well as covering an internal in-frame methionine. While AUG overlap is 
crucial to retain SINEUP activity when targeting over-expressed mRNAs (100), we 
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prove it is not for endogenous transcripts. In addition, shrinking the BD down to 14 
nts still maintains strong target protein up-regulation. 
The vast majority of RNA-based therapeutics has been demonstrated to be too 
charged and/or too large to enter cells (21). Therefore, SINEUPs miniaturization is 
required to favour its delivery (95). Here we provide further evidence that 
miniSINEUP-FXNs are equally active than their longer counterparts. Chemical 
footprinting of invSINEB2 has recently identified several structural regions that are 
required for the ability of AS Uchl1 to increase translation, including a short terminal 
stem loop hairpin structure (SL1) as key structural determinant (96). Therefore, it is 
tempting to speculate that an even shorter and more active ED could be obtained based 
on structural data, thus providing further optimization of SINEUPs towards their 
therapeutic application (Gustincich S., unpublished; Carninci P., unpublished). 
Finally, we demonstrate for the first time that FXN expression can be targeted 
specifically at translational level, providing evidence that synthetic SINEUPs and 
miniSINEUPs positively regulate frataxin in human healthy cell lines (from 20% to 
50%). More importantly, FRDA-derived fibroblasts and lymphoblasts showed an 
accumulation of mature frataxin in the range of two folds of the amounts in untreated 
cells, without increasing FXN mRNA levels. In this context, miniSINEUP-FXN 
targeting the first AUG in FRDA lymphoblasts re-establishes FXN physiological 
levels, indistinguishable from those of healthy controls. The role of frataxin as 
activator of the ISC biosynthetic machinery (168,173,174) and as iron-chaperone, that 
provides ferrous iron in a bioavailable form (224-226), are the most well-defined 
molecular functions for this protein. In this context, frataxin is dually linked to cellular 
aconitases activity. The role of frataxin in the biosynthesis of ISC impacts on cellular 
availability of the prosthetic group required for both enzymes’ function (227). 
Furthermore, frataxin can physically interact with mitochondrial and cytosolic 
aconitase, with the ability to protect or reactivate the enzyme’s cofactor (226,228). 
Accordingly, rescue of aconitase defects has been associated to therapeutic increase of 
frataxin levels in cellular and animal models of FRDA (183,197,218,229). Therefore, 
we proved that the additional frataxin protein, as induced by miniSINEUPs, was 
functional and able to rescue the activity of ISC-dependent enzymes to physiological 
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levels in patient’s lymphoblasts. It is striking that we observed the recovery of more 
than 90% of aconitase activity in presence of the most effective miniSINEUP-FXN. 
In conclusion, we provide strong evidence that synthetic SINEUPs enhance 
endogenous protein expression to the physiological range in a cellular model of a 
monogenic disease.  
Their ability to revert pathophysiological phenotypes in human patients’ cells 
warrants the pre-clinical evaluation of a SINEUP-based therapy to treat FRDA. More 
broadly, these evidences support that synthetic SINEUPs represent a scalable platform 
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SUPPLEMENTARY FIRGURES & TABLES 
SUPPLEMENTARY FIGURE S1 
Cloning Oligo Name: Sequence (5’ → 3’): Features: 
FXN.9 FWD TCGAGGCTGCTCCGGGTCTGCCGCCCGCTCCGCCCTCCAGCGCTG BD 
FXN.9 REV CAGCGCTGGAGGGCGGAGCGGGCGGCAGACCCGGAGCAGCC BD 
FXN.10 FWD TCGAGGCTGCTCCGGGTCT BD 
FXN.10 REV AGACCCGGAGCAGCC BD 
FXN.11 FWD TCGAGACATGCTGCTCCGGGTCT BD 
FXN.11 REV AGACCCGGAGCAGCATGTC BD 
FXN.12 FWD TCGAGTCATCAAATAGACACTCTGCTTTTTGACATTCCAAATCTGGTTG BD 
FXN12. REV CAACCAGATTTGGAATGTCAAAAAGCAGAGTGTCTATTTGATGAC BD 
FXN.13 FWD TCGAGCAAATAGACACTCTGCTTTTTGACATTCCAAATCTGGTTG BD 
FXN13. REV CAACCAGATTTGGAATGTCAAAAAGCAGAGTGTCTATTTGC BD 
FXN.14 FWD TCGAGCAAATAGACACTCTGCTTTTTGACATTCCAAATCTGGTTGAGGCCACGTTGGTTCGAACTTGCGCGGCGG BD 
FXN14. REV CCGCCGCGCAAGTTCGAACCAACGTGGCCTCAACCAGATTTGGAATGTCAAAAAGCAGAGTGTCTATTTGC BD 
SyberGreen Assay    
qRT-PCR Oligo 
Name: 
Sequence (5’ → 3’): Features: 
hGAPDH FWD TCTCTGCTCCTCCTGTTC Housekeeping gene 
hGAPDH REV GCCCAATACGACCAAATCC Housekeeping gene 
mAS3' Uchl1 FWD CTGGTGTGTATTATCTCTTATGC ED (SINEUP) 
mAS3' Uchl1 REV CTCCCGAGTCTCTGTAGC ED (SINEUP) 
pTSinvB2 FWD CAGTGCTAGAGGAGGTCAGAAGA ED (miniSINEUP) 
pTSinvB2 REV GGAGCTAAAGAGATGGCTCAGCACTT ED (miniSINEUP) 
hFXN FWD1 GTGATCAACAAGCAGACGCCAAACAAGCA FRDA Fibroblast 
hFXN REV1 GTACACCCAGTTTTTCCCAGTCCAGTCA FRDA Fibroblast 
hFXN FWD2 CCTTGCAGACAAGCCATACACGTTTGAG FRDA Fibroblast 
hFXN REV2 CTGCTTGTTGATCACATAGGTTCCTAGATC FRDA Fibroblast 
hFXN FWD GGAAACGCTGGACTCTTTAGC Human Cell lines 




Sequence (5’ → 3’): Features: 
FXN Hs00175940_m1 Target 
hGAPDH Hs99999905_m1 Housekeeping gene 
GUSB Hs00939627_m1 Housekeeping gene 
ACTB Hs99999903_m1 Housekeeping gene 
miniSINEUP ED FWD GGTCAGAAGAGGGCATTGGA, ED (miniSINEUP) 
miniSINEUP ED REV CCACCACGAGGTTACCGTATAAC ED (miniSINEUP) 
Probe CCCCCAGAACTGG ED Probe 
Figure S1 – List of primers. Complete list of oligonucleotides used in this study for cloning and quantitative 
PCR experiments. 
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Figure S2 – miniSINEUP specificity. a) Blast analysis of miniSINEUPs BDs off-targets against Human 
Genome transcripts; highlighted in red chosen off-targets for each BD; b) Off-targets protein levels were 
analyzed by western blot with anti-stx1b, anti-fam49, anti-gcp5 antibodies staining and off-target protein levels 
were calculated relative to empty control samples (fold changes are shown); analysed protein lysates are relative 
to replicas of miniSINEUPs activity experiments (Figure 25); c) Summary of data of protein quantities. Data 
indicate mean ± SEM and are representative of four independent experiments. p values are calculated by 




SUPPLEMENTARY FIGURE S3 
 
Figure S3 - Setup of inducible lentiviral delivery of miniSINEUP in vitro in human cell lines. a) Schematic 
overview of Single Induction and Double Induction protocol used with lentiviral vectors expressing 
miniSINEUP-FXN. The time of Infection, Induction of expression (Doxo Treatment) and Collection of RNA 
and protein samples are shown. (b) Human neuroblastoma SH-SY5Y cells were infected with lentiviral vectors 
expressing miniSINEUPs (LV miniSINEUP) or empty control virus (-) as indicated and following the Single 
Induction or Double Induction protocols. Protein levels were analyzed by western blot with anti-FXN antibody 
and SINEUP activity was calculated as increase in protein levels relative to empty control samples (fold changes 
are shown). Scatter plot graph (bottom) shows summary of results (frataxin protein fold-induction). Data 
indicate mean ± SEM and are representative of three independent experiments. p values are calculated by 
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